Application of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for the treatment of preeclampsia

Treatment of preeclampsia through nanomicrovesicles derived from mesenchymal stem cells, the problem of ineffective treatment of preeclampsia in the prior art was solved, significantly lowering the blood pressure and proteinuria in rats, improving fetal development, and providing treatment from the perspective of etiology Effect.

CN114081900BActive Publication Date: 2024-11-22AFFILIATED HOSPITAL OF JINING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110207297.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-02-24
Publication Date
2024-11-22
Estimated Expiration
2041-02-24

AI Technical Summary

Technical Problem

There is no effective treatment method to prolong pregnancy and avoid adverse fetal consequences. Currently, the only treatment method for preeclampsia is to terminate pregnancy, which leads to premature birth of the fetus and cardiopulmonary immaturity. Commonly used drugs such as magnesium sulfate only play a role in lowering blood pressure. Not from the perspective of cause.

Method used

Nanomicrovesicles from mesenchymal stem cells were used to extract microvesicles secreted by hucMSCs from the umbilical cord, and prepared through in vitro amplification, ultrafiltration, density gradient centrifugation and other steps. They were used in the treatment of preeclampsia and used in rat models. The treatment significantly lowers blood pressure and 24-hour proteinuria, improving fetal development.

Benefits of technology

It significantly reduces the blood pressure and 24-hour proteinuria in rats, increases the weight of fetal and placenta, improves fetal development, and provides therapeutic effects from the perspective of etiology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114081900B_ABST
    Figure CN114081900B_ABST
Patent Text Reader

Abstract

The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for treating preeclampsia, belonging to the field of biological medicine technology. The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for treating preeclampsia. Experiments have shown that after extracting secreted microvesicles from umbilical cord mesenchymal stem cells, they are used to treat preeclampsia rat animal models. The hucMSC-derived microvesicles have the effect of reducing blood pressure and 24h proteinuria in preeclampsia model rats, improving preeclampsia-like symptoms in rats, and can increase the weight of offspring and improve fetal development, providing a new direction for the treatment of preeclampsia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological medicines, and in particular relates to the application of nano-microvesicles derived from mesenchymal stem cells in the preparation of medicines for treating preeclampsia. Background Art

[0002] Preeclampsia is a serious complication of pregnancy, with an incidence of about 5% to 8%, and is the leading cause of maternal mortality worldwide. Preeclampsia can lead to fetal growth restriction or even death. Although preeclampsia has a significant impact on the health of pregnant women and fetuses, there is currently no effective treatment that can prolong pregnancy without causing adverse consequences to the fetus. At present, termination of pregnancy is still the only treatment for preeclampsia, leading to adverse outcomes such as premature birth and cardiopulmonary immaturity of the fetus. In addition, the most commonly used clinical treatment drugs include magnesium sulfate, but long-term and large-scale use can cause certain side effects, and only from the perspective of the symptoms of the disease, it mainly plays a hypotensive role, not a therapeutic role from the perspective of etiology. Therefore, actively exploring new treatment options for preeclampsia and revealing its mechanism of action has important scientific significance and clinical translation value.

[0003] In recent years, mesenchymal stem cells (MSCs) have attracted much attention in the medical field for their multipotency and paracrine ability. However, the ethical, safety, difficult storage and transportation of stem cells limit their clinical application. In recent years, microvesicles, an important component of MSCs paracrine, have been reported to be widely involved in many physiological and pathological processes of diseases such as cell invasion and migration, immune regulation, angiogenesis and tissue regeneration. Compared with MSCs, microvesicles derived from mesenchymal stem cells have the advantages of convenient transportation, good biosafety and high targeting. Umbilical cord has long been proven to be one of the high-quality sources of microvesicles secreted by MSCs. Compared with microvesicles secreted by MSCs from other sources, microvesicles secreted by umbilical cord MSCs have the advantages of no ethical controversy, stable and safe genes, convenient collection and low immunogenicity. The microvesicle structure is an important pathway for intercellular signal communication discovered in recent years and is an important paracrine form other than cell-soluble cytokines. At present, MSCs-derived microvesicles play a role in the repair and regeneration of tissue damage, mainly by delivering MSCs-derived proteins, lipids, mRNA, miRNA and other substances and mediating paracrine pathways, which enable surviving cells in damaged tissues to re-enter the cell cycle. At the same time, they can obtain tissue specificity through bidirectional exchange of genetic materials with MVs released by damaged cells, further repairing damaged tissues. However, there is no report in the prior art that MSCs-derived microvesicles can be used to treat preeclampsia. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a use of nano-microvesicles derived from mesenchymal stem cells in the preparation of a drug for treating preeclampsia.

[0005] The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of a medicine for treating preeclampsia.

[0006] Preferably, the method for preparing the mesenchymal stem cell-derived nano-microvesicles comprises the following steps:

[0007] 1) hucMSCs were expanded and cultured in vitro, and when the cell confluence reached 75% to 80%, the culture supernatant was collected, and cell fragments were removed to obtain MSC-CM;

[0008] 2) removing cell debris and organelles from the MSC-CM, performing ultrafiltration washing, and collecting the concentrate;

[0009] 3) transferring the concentrated solution to a sucrose / D2O density pad with a mass concentration of 30% for density gradient centrifugation, and collecting the bottom buffer pad;

[0010] 4) After the bottom buffer pad is diluted and washed, the ultrafiltration washing is performed, and the microvesicle concentrate is collected and sterilized to obtain nano-microvesicles derived from mesenchymal stem cells.

[0011] Preferably, the method for removing cell fragments in step 1) comprises centrifugation; the centrifugal force of the centrifugation is 1800-2200g, and the centrifugation time is 8-12min.

[0012] Preferably, the removal of cell debris and organelles in step 2) comprises differential centrifugation; the centrifugal force of the differential centrifugation is 1500-2200 rpm, and the time of the differential centrifugation is 15-30 min.

[0013] Preferably, the ultrafiltration washing in step 2) or step 4) is performed using a 100,000Da MWCO ultrafiltration centrifuge tube.

[0014] Preferably, the centrifugal force of the density gradient centrifugation in step 3) is 100000 g, the time of the density gradient centrifugation is 3 h; and the temperature of the density gradient centrifugation is 4°C.

[0015] Preferably, the surface marker proteins of the mesenchymal stem cell-derived nano-microvesicles include CD63 and CD9.

[0016] Preferably, the dosage form of the drug is an injection; in the injection, the concentration of nano-microvesicles derived from mesenchymal stem cells is not less than 4.5×10 11 Number of particles / 0.4ml.

[0017] The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for treating preeclampsia. After extracting secreted microvesicles from umbilical cord mesenchymal stem cells, they are used to treat preeclampsia rat animal models. It is found that hucMSC has the effect of reducing blood pressure and 24h proteinuria in preeclampsia model rats, improving preeclampsia-like symptoms in rats, and can increase the weight of offspring and improve fetal development. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIG1 is the identification result of hucMSC microvesicles separated and purified by the present invention; Figure 1A This is an electron microscope image; Figure 1B The size distribution results of hucMSC microvesicles; Figure 1C The results of western blot technology detection;

[0019] Figure 2 Flow chart for modeling PE rat model and hucMSC microvesicle intervention;

[0020] Figure 3 is a diagram showing the results of determining rat pregnancy, where Figure 3A This is an electron microscopic image of a vaginal suppository; Figure 3B To obtain vaginal discharge scene map; Figure 3C For vaginal smear results;

[0021] Figure 4 shows the test results of the successfully constructed PE model rats; Figure 4A This is a bar graph of 24h proteinuria level in rats; Figure 4B It is a bar graph of blood pressure of rats;

[0022] Figure 5 To improve the preeclampsia-like symptoms of PE rats by using hucMSC microvesicles;

[0023] FIG6 is a graph showing the effect of hucMSC microvesicles on the weight of PE mice, litter size and placenta weight in the treatment of preeclampsia. Fig. 6A is the average fetal weight, Figure 6B is the average placenta weight. DETAILED DESCRIPTION

[0024] The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of a medicine for treating preeclampsia.

[0025] In the present invention, the method for preparing the mesenchymal stem cell-derived nano-microvesicles preferably comprises the following steps:

[0026] 1) hucMSCs were expanded and cultured in vitro, and when the cell confluence reached 75% to 80%, the culture supernatant was collected, and cell fragments were removed to obtain MSC-CM;

[0027] 2) After removing cell debris and organelles from MSC-CM, ultrafiltration and washing are performed to collect the concentrate;

[0028] 3) transferring the concentrated solution to a sucrose / D2O density pad with a mass concentration of 30% for density gradient centrifugation, and collecting the bottom buffer pad;

[0029] 4) After the bottom buffer pad is diluted and washed, the ultrafiltration washing is performed, and the concentrated liquid is collected and sterilized to obtain nano-microvesicles derived from mesenchymal stem cells.

[0030] The present invention expands and cultures hucMSC in vitro, collects culture supernatant when the cell confluence reaches 75% to 80%, removes cell fragments, and obtains MSC-CM.

[0031] In the present invention, the method for in vitro expansion and culture of hucMSC can refer to the prior art (Qiao Chun et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 2008 Jan; 32 (1): 8-15.). In the embodiment of the present invention, hucMSC is purchased from Saiye Biotech. The hucMSC is preferably healthy human hucMSC with strong proliferation ability and good condition, for example, the third or fourth generation cells are selected for in vitro expansion and culture. The culture preferably uses serum-free medium.

[0032] In the present invention, the method for removing cell fragments preferably comprises centrifugation; the centrifugal force of the centrifugation is preferably 1800-2200g, more preferably 2000g; the time of the centrifugation is preferably 8-12min, more preferably 10min.

[0033] After obtaining MSC-CM, the present invention removes cell debris and organelles from the MSC-CM, performs ultrafiltration washing, and collects the concentrated solution.

[0034] In the present invention, the removal of cell debris and organelles preferably includes differential centrifugation; the centrifugal force of the differential centrifugation is preferably 1500-2200rpm, more preferably 2000rpm. The time of the differential centrifugation is preferably 15-20min, more preferably 20min. The ultrafiltration washing is preferably carried out using a 100000Da MWCO ultrafiltration centrifuge tube. The present invention does not specifically limit the source of the 100000Da MWCO ultrafiltration centrifuge tube, and the source of the 100000Da MWCO ultrafiltration centrifuge tube well known in the art can be used.

[0035] After obtaining the concentrated solution, the present invention transfers the concentrated solution to a sucrose / D2O density pad with a mass concentration of 30% to perform density gradient centrifugation, and collects the bottom buffer pad.

[0036] In the present invention, the centrifugal force of the density gradient centrifugation is preferably 100000g, the time of the density gradient centrifugation is preferably 3h; the temperature of the density gradient centrifugation is preferably 4°C. The present invention has no special restrictions on the preparation of the 30% mass concentration sucrose / D2O density pad, and the preparation method of the 30% mass concentration sucrose / D2O density pad known in the art can be used. The microvesicles are settled to the bottom through density gradient centrifugation, and the bottom buffer pad is collected for subsequent purification.

[0037] After the bottom buffer pad is obtained, the present invention dilutes and washes the bottom buffer pad, performs ultrafiltration washing, collects the microvesicle concentrate, and sterilizes to obtain nano-microvesicles derived from mesenchymal stem cells.

[0038] In the present invention, the dilution and washing solution is preferably a PBS buffer with a pH of 7.4. The dilution multiple of the bottom buffer pad with the PBS buffer is preferably 2 to 10 times, more preferably 10 times.

[0039] In the present invention, the ultrafiltration washing preferably transfers the obtained diluted solution to a 100000Da MWCO ultrafiltration centrifuge tube to collect the microvesicle concentrate. The sterilization preferably adopts membrane filtration sterilization; the pore size of the filter membrane is preferably 0.22 μm.

[0040] In the present invention, the obtained mesenchymal stem cell-derived nano-microvesicles are preferably identified. The identification includes basic morphological identification and identification of surface marker proteins. The basic morphological identification includes observing the separated and purified nano-microvesicles by transmission electron microscopy. The transmission electron microscopy images show that the microvesicles have a typical vesicle structure with a particle size of about 100nm. The identification of the surface marker proteins is preferably detected by western blot technology. The proteins detected by the western blot technology preferably include CD63 and CD9 and the negative marker Calnexin. The results show that the surface marker proteins of the mesenchymal stem cell-derived nano-microvesicles separated and purified by the present invention preferably include CD63, CD9 and Calnexin.

[0041] In the present invention, the dosage form of the drug is preferably an injection; in the injection, the concentration of the nano-microvesicles derived from mesenchymal stem cells is preferably not less than 4.5×10 11 Number of particles / 0.4ml.

[0042] In the present invention, by constructing a preeclampsia rat model, the isolated and purified mesenchymal stem cell-derived nano-microcapsules were treated with low and high doses, respectively. The urine protein level and blood pressure of the rats were measured. The results showed that high-dose hucMSC microcapsules can significantly reduce the blood pressure and 24h proteinuria level of rats, while low-dose hucMSC microcapsules can significantly reduce the blood pressure of rats, but the statistical difference in 24h urine protein level was not significant, only showing a downward trend. At the same time, the present invention also evaluates the effect of hucMSC microcapsule treatment on fetal and placental weight. The results show that both high- and low-dose treatment groups can increase the average weight of offspring, and the high-dose treatment group can increase the average placental weight and improve fetal development outcomes.

[0043] The application of the nano-microvesicles derived from mesenchymal stem cells provided by the present invention in the preparation of a drug for treating preeclampsia is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0044] Example 1

[0045] Method for obtaining hucMSC microvesicles (MVC)

[0046] 1. The main materials and sources are as follows:

[0047] 1.1 Reagents: low-glucose DMEM, trypsin (Sigma), fetal bovine serum (Gibco), serum-free culture medium (Shanghai Yikesai Company), microvesicle extraction reagents: heavy water (D2O, Shanghai Chuangsai Company), analytical grade sucrose (Guangzhou Chemical Reagent Factory), rabbit anti-human CD9 antibody (Bioworld Technology, USA), rabbit anti-human CD63 antibody (Epitomics, USA), rabbit anti-human Calnexin antibody (abcam, USA), BCA protein quantification kit, horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG secondary antibody (Beijing Kangwei Century Company), HRP chemiluminescent substrate;

[0048] 1.2 Instruments and consumables: CO2 incubator (Forma); desktop gradient centrifuge, electron microscope, inverted microscope, biological microscope, clean bench, 100-kDa MWCO ultrafiltration centrifuge tube, 0.22 μm sterile filter membrane (Millipore, USA), transmission electron microscope (FEI Tecnai 12, Philips), and filter membrane.

[0049] 2. Experimental Methods

[0050] (1) Isolation and culture of hucMSCs:

[0051] MSCs were cultured and expanded in vitro according to the hucMSC isolation, culture and identification method established earlier by our research group (QiaoChun et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 2008 Jan; 32(1): 8-15). Healthy human hucMSCs (third or fourth generation) with strong proliferation ability and good condition were selected. After the growth area covered 80%, serum-free culture medium was added. The culture supernatant was collected and centrifuged at 2000g / 10min to remove cell debris to obtain hucMSC-CM, which was stored at -80℃ and used for the extraction of microvesicles.

[0052] (2) Isolation and purification of umbilical cord mesenchymal stem cell microvesicles:

[0053] The collected hucMSC-CM was removed of cell debris and organelles by differential centrifugation and then transferred to a 15 mL 100,000 Da MWCO ultrafiltration centrifuge tube for concentration. The concentrate was transferred to a 5 mL 30% sucrose / D2O density pad and centrifuged at 100,000 g for 3 h at 4°C. The 5 mL buffer pad (containing microvesicles) at the bottom was collected and diluted and washed with PBS, and then placed in a 100,000 Da MWCO ultrafiltration centrifuge tube for washing. Finally, the collected microvesicle concentrate was quantified, filtered and sterilized with a 0.22 μm filter membrane, and the number of microvesicle particles in the microvesicles was determined by the Nanosigt method and packaged, and refrigerated at -80°C for later use.

[0054] (3) Identification of umbilical cord mesenchymal stem cell microvesicles

[0055] The basic morphology of the umbilical cord mesenchymal stem cell microvesicles isolated and purified above was observed under a transmission electron microscope. The specific method was as follows: 20 μL of umbilical cord mesenchymal stem cell microvesicles was fully mixed and then dropped onto a sample-carrying copper mesh with a diameter of 2 mm. After standing at room temperature for 5 min, the residual liquid at the edge of the copper mesh was gently absorbed with filter paper, and then the copper mesh was inverted on a drop of 30 g / L phosphotungstic acid (pH 6.8) and negatively stained at room temperature for 5 min. Finally, the copper mesh was dried under an incandescent lamp, observed under a transmission electron microscope and photographed. The results are shown in Figure 1-A.

[0056] The surface marker protein of the microvesicles was detected by western blot technology. The specific method was as follows: 12% SDS-PAGE electrophoresis gel was prepared, and the microvesicles extracted above were fully lysed and then 1 / 4 volume of 5×SDS loading buffer was added, boiled for 5 minutes, and 200 μg of protein was loaded. The protein was transferred to a PVDF membrane by electrotransfer (350 mA, 120 minutes), and blocked with TBS / T containing 50 g / L skim milk at room temperature for 1 hour, and reacted with rabbit anti-human CD9 antibody and rabbit anti-human CD63 antibody (1:500) at 4°C overnight, and washed the membrane with TBS / 0.5% Tween 20 3 times the next day, and incubated with HRP-labeled goat anti-rabbit IgG secondary antibody at 37°C for 1 hour), and washed the membrane with TBS / 0.5% Tween 20 3 times, and then premixed HRP chemiluminescent substrate was added, and detected by a chemiluminescent gel imaging system, as shown in the attached Figure 1C Shown are the expression of marker proteins in umbilical cord-derived microvesicles.

[0057] Example 2

[0058] Method for constructing a rat model of preeclampsia

[0059] 1. Materials and reagents: 10-week-old healthy SD female rats (200-250 g) and male rats (200-250 g) were purchased from Jinan Pengyue Experimental Animal Co., Ltd., ordinary feed (Jinan Pengyue Experimental Animal Co., Ltd.), disposable syringes, L-NAME, physiological saline, rat metabolic cages, fully automatic biochemical analyzer (Roche, Switzerland) and fully automatic non-invasive blood pressure monitor (Softron Company, Beijing, China), etc.

[0060] 2. Experimental methods (see Figure 2 ):

[0061] Construction of rat eclampsia model: 10-week-old healthy SD female and male rats were fed for 1 week and then numbered and caged at 8 pm in a ratio of 2:1. The next morning at 7 am, the female and male rats were separated and the vaginal plug was checked. If a vaginal plug was seen, Figure 3A ) is considered the first day of pregnancy. Vaginal secretions are collected when the vaginal plug cannot be seen ( Figure 3B ) vaginal smear to observe sperm and epithelial cells ( Figure 3C ). If there is sperm on the slide, that day is considered the first day of pregnancy.

[0062] Pregnant rats were randomly divided into 2 groups: normal control group (Control) and PE model group; L-NAME (nitroso-L-arginine methyl ester) was intraperitoneally injected into the PE model group, high-concentration microvesicle group and low-concentration microvesicle group from the 7th to the 19th day of pregnancy, 250 mg / kg / d. Normal saline was intraperitoneally injected into the normal control group from the 7th to the 19th day of pregnancy. The blood pressure was monitored on the 6th day (the day before L-NAME injection), 10th day and 13th day of pregnancy using a BP2010 fully automatic non-invasive blood pressure monitor. On the 6th day (the day before L-NAME injection), 10th day and 13th day of pregnancy, the 24-hour urine protein level of the rats was measured using a fully automatic biochemical analyzer.

[0063] The results showed that the blood pressure in the model group was higher than that in the normal group by more than 30 mmHg ( Figure 4A ), 24-hour urine protein level increased significantly ( Figure 4B ). The above results showed that the PE model rats were successfully established.

[0064] Example 3

[0065] Evaluation of the therapeutic effect of hucMSC microvesicles on preeclampsia rats

[0066] 1. Required materials and reagents: disposable syringes, hucMSC microvesicles, normal saline, rat metabolic cages, fully automatic biochemical analyzer, fully automatic non-invasive blood pressure monitor, sodium pentobarbital, and dose balance.

[0067] 2. Experimental Methods

[0068] Treatment steps and effect evaluation of HucMSC microvesicles:

[0069] Set up four groups:

[0070] Control group: Normal saline was injected into the tail vein starting at 14 days old, 0.4 ml / rat / day, for 6 days;

[0071] PE group: starting from the 14th day, normal saline was injected into the tail vein, 0.4 ml / rat / day, for a total of 6 days;

[0072] Low-concentration microvesicle group (PE+L-MVS): Starting from the 14th day, the tail vein injection volume (0.4 ml) was 2.25×10 11 Microvesicle suspension with a particle number, 0.4 ml / rat / day, for 6 days;

[0073] High-concentration microvesicle group (PE+H-MVS): Starting from the 14th day, the tail vein injection volume (0.4 ml) was 4.5×10 11 Microvesicle suspension with a particle size of 0.4 ml / rat / day for 6 days.

[0074] 1) Monitor blood pressure and 24-hour urine protein level on the 16th and 19th days of pregnancy respectively.

[0075] The results are shown in Table 1 and Figure 5 .

[0076] Table 1 Blood pressure and proteinuria test results of rats in each experimental group and control group

[0077]

[0078] Note: All data are expressed as "mean ± standard deviation". Different letters in the same row indicate that the difference reaches a significant level of 0.01.

[0079] The results showed that high-dose hucMSC microvesicles could significantly reduce the blood pressure and 24-hour proteinuria level of rats, while low-dose hucMSC microvesicles could significantly reduce the blood pressure of rats, but the statistical difference in the 24-hour urine protein level was not significant, but there was a downward trend.

[0080] 2) Observation and evaluation of the effect of HucMSC microvesicles on fetal and placental weight:

[0081] Rats were anesthetized with 3% sodium pentobarbital solution. After anesthesia, cesarean section was performed immediately to remove the fetus and placenta, suture the uterus and abdomen, and count the normal-sized fetuses and placentas. After removing the fetal membranes and umbilical cord on the placenta, the umbilical cord connected to the fetus was cut, and the fetus and placenta were placed on sterile gauze to absorb blood and amniotic fluid. Subsequently, the fetus and placenta were weighed separately on an analytical balance.

[0082] The results are shown in Table 2 and Figure 6.

[0083] Table 2 Fetal and placenta weights

[0084] Control PE PE+L-MVS PE+H-MVS Fetal weight (g) <![CDATA[3.006±0.103 a ]]> <![CDATA[2.635±0.245 b ]]> <![CDATA[2.932±0.086 a ]]> <![CDATA[2.981±0.058 a ]]> Placenta weight (g) <![CDATA[0.453±0.051 a ]]> <![CDATA[0.351±0.046 b ]]> <![CDATA[0.389±0.038 ab ]]> <![CDATA[0.429±0.051 a ]]>

[0085] Note: All data are expressed as "mean ± standard deviation". Different letters in the same row indicate that the difference reaches a significant level of 0.05.

[0086] The results showed that both the high-dose and low-dose treatment groups could increase the average weight of the offspring, and the high-dose treatment group could increase the average placental weight and improve the fetal development outcomes.

[0087] From the results of the above examples, it can be seen that the use of HucMSC microcapsules to treat preeclampsia can not only improve the blood pressure and urine protein indicators of the pregnant mother, but also significantly increase the weight of the fetus and the weight of the placenta, and can improve the development of the fetus.

[0088] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of nano-microvesicles derived from mesenchymal stem cells in the preparation of a drug for treating preeclampsia, wherein the preeclampsia is L-NAME-induced preeclampsia; The method for preparing the nano-microvesicles derived from mesenchymal stem cells comprises the following steps: 1) culturing hucMSC in vitro, collecting the culture supernatant when the cell confluence reaches 75% to 80%, removing cell fragments, and obtaining MSC-CM; the hucMSC in vitro proliferation culture adopts serum-free culture medium; 2) removing cell debris and organelles from the MSC-CM, washing it with ultrafiltration, and collecting the concentrate; 3) transferring the concentrated solution to a sucrose / D2O density pad with a mass concentration of 30% for density gradient centrifugation, and collecting the bottom buffer pad; the centrifugal force of the density gradient centrifugation is 100000g, the time of the density gradient centrifugation is 3h; the temperature of the density gradient centrifugation is 4°C; 4) After diluting and washing the bottom buffer pad, performing the ultrafiltration washing, collecting the microvesicle concentrate, sterilizing, and obtaining nano-microvesicles derived from mesenchymal stem cells; The molecular weight cut-off of the ultrafiltration washing in step 2) or step 4) is 100000Da; The dosage form of the drug is an injection; in the injection, the concentration of nano-microvesicles derived from mesenchymal stem cells is not less than 4.5×10 11 Number of particles / 0.4ml; The method for removing cell fragments in step 1) includes centrifugation; the centrifugal force of the centrifugation is 1800-2200g, and the centrifugation time is 8-12min; Removing cell debris and organelles in step 2) includes differential centrifugation; the centrifugal force of the differential centrifugation is 1500-2200 rpm, and the time of the differential centrifugation is 15-30 min; The surface marker proteins of the nano-microvesicles derived from mesenchymal stem cells include CD63 and CD9.

2. The application according to claim 1, characterized in that: The ultrafiltration washing in step 2) or step 4) is performed using a 100000Da MWCO ultrafiltration centrifuge tube.